All News / Outbreaks /

Bioniche Life Sciences Inc. Receives Government of Canada Support for Second Generation E. coli O157:H7 Vaccine

Bioniche Life Sciences Inc. (asx:BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has received a contribution of up to 500,000 from the National Research Council of Canada Industrial Research Assistance Program (IRAP) for the Company’s research and development of a second generation E. coli O157 cattle vaccine. IRAP’s support will offset salary costs and contractor fees associated with the project for the next three years.

“We are pleased to receive this funding from IRAP,” said Mr. Rick Culbert, President, Bioniche One Health. “We have been working with Dr. Brett Finlay at the University of British Columbia on the development of a second generation E. coli O157 cattle vaccine, which is expected to be safer to make, more readily produced with higher yields than the first generation vaccine, and may have the potential to cross-protect against other E. coli serotypes.”

While development of the second generation vaccine continues in coming years, the Company’s first generation E. coli O157 cattle vaccine – Econiche – is fully registered in Canada and is available through Canadian veterinarians. In Australia, although not yet registered, the vaccine is approved for importation. In the UK, the product has received Special Treatment Certificate authorization, allowing veterinary surgeons to use the vaccine on visitor open farms.

Human illnesses stemming from E. coli O157 have been linked to beef products (particularly ground beef), vegetables, fruit, juice, water, and contact with animals at petting zoos, farms, and fairs. Approximately two-thirds of all illnesses are associated with contaminated produce and water or direct contact, while one-third are associated with contaminated beef. When humans are infected with E. coli O157, symptoms begin within 3-10 days. These can range from diarrhea and fever to severe bloody diarrhea to Haemolytic Uremic Syndrome (HUS) and death. Long-term studies following patients infected with E. coli O157 have documented secondary illnesses due to hypertension, cardiovascular and kidney disease as well as arthritis.

Approximately 100,000 cases of human infection with E. coli O157 are reported each year in North America. More than 20,000 of these cases are seen in Canada, where the cost of primary and long-term illnesses has been estimated at 240 million per year.

“There is compelling evidence to show that immunization of cattle against E. coli O157 will reduce the shedding of this deadly pathogen, and several modeling studies have been done to demonstrate that human illness would be reduced as a result of this reduction in shedding,” added Mr. Culbert. “Since E. coli O157 does not make cattle ill, the rationale for cattle vaccination is to reduce the amount of E. coli O157 being shed into food, water, and the environment and, in turn, to reduce exposure by people.”

The Company will also explore the ability of the second generation vaccine to cross-protect against other E. coli serotypes. Although E. coli O157 is the most common serotype causing human infection in North America, other serotypes, including O26, O111, O103, O121, O45 and O145, have been identified in other jurisdictions.

Both Econiche and the second generation E. coli O157 vaccine will be produced in the Company’s Animal Health and Food Safety Vaccine Manufacturing Centre in Belleville, which is currently undergoing validation to Good Manufacturing Practice (GMP) standards for global production. GMP validation is now expected to be completed by summer, 2013.

Get Help

Affected by an outbreak or recall?

The team at Marler Clark is here to answer all your questions. Find out if you’re eligible for a lawsuit, what questions to ask your doctor, and more.

Get a free consultation
Related Resources
E. coli Food Poisoning

What is E. coli and how does it cause food poisoning? Escherichia coli (E. coli) is a highly studied, common species of bacteria that belongs to the family Enterobacteriaceae, so...

E. coli O157:H7

E. coli O157:H7 is a foodborne pathogen that causes food poisoning. E. coli O157:H7 is the most commonly identified and the most notorious Shiga toxin-producing E. coli (STEC) serotype in...

Non-O157 STEC

Non-O157 Shiga Toxin-Producing E. coli can also cause food poisoning. E. coli O157:H7 may be the most notorious serotype of Shiga toxin-producing E. coli (STEC), but there are at least...

Sources of E. coli

Where do E. coli O157:H7 and non-O157 Shiga toxin-producing E. coli (STEC) come from? The primary reservoirs, or ultimate sources, of E. coli O157:H7 and non-O157 STEC in nature are...

Transmission of and Infection with E. coli

While many dairy cattle-associated foodborne disease outbreaks are linked to raw milk and other raw dairy products (e.g., cheeses, butter, ice cream), dairy cattle still represent a source of contamination...

Outbreak Database

Looking for a comprehensive list of outbreaks?

The team at Marler Clark is here to answer all your questions. Find out if you’re eligible for a lawsuit, what questions to ask your doctor, and more.

View Outbreak Database